Key features
as of 30/04/2020
  • SRI labelled European thematic equity sub-fund, with a very defensive long-only management style.
  • Track record of almost 18 years.
  • Since its launch, the sub-fund has remained very resilient in periods of high volatility: 2011, 2016, 2018 and March 2020.
  • YTD performance -6.9% vs -19.8% of the Euro Stoxx TR.
  • Historic Beta (3 years): 0.66.
  • Annualized volatility (3 years): 13.0%.
  • The management style follows the GARP model (i.e. growth at a reasonable price): the investment process focuses on growth stocks, but with not overpriced and resilient valuations. Shared, because managers focus on companies that can have a positive impact on society.
  • In addition, Sycomore decided to dedicate part of the management fees generated by the fund to non-profit institutions that support projects of high social value.
Fund ManagersFrédéric Ponchon and Sara Carvalho de Oliveira (SRI Analyst)
Management Company and Investments ManagerSycomore AM
AuM358 mln
ISIN FR0010117085 (Eur I Acc.)
Launch of sub-fund24/06/2002
BenchmarkEuro Stoxx Total Return
Fund CurrencyEuro
Management fees1.00%
Performance fees 20% > benchmark

as of 30/04/2020
Sycomore Shared Growth | Eur I Acc.

SI (annualised)

Performance data shown represents past performance and is no guarantee of, and not necessarily indicative of, future results. No express or implied liability or guarantee is assumed that the future performance will correspond to the performance described above. The value of and income from fund units or sub-fund units ("Units") may fluctuate, rise or fall, so you may have a gain or a loss when the Units are sold. The performance of and income from the Units have to be reduced by costs and taxes. Current performance may be higher or lower than the quoted and no guarantee can be assumed that the investment objectives of the fund/sub-fund will be achieved.

Fund commentary | April 2020

The market rebounded sharply in April, lifted by the economic response plans announced by governments and central banks, but also by investors’ perception that the peak of the epidemic is now over and that treatments, but also vaccines, are on the horizon. Sycomore Shared Growth outperformed thanks to the particularly strong returns posted by the health care industry. Ipsen rallied sharply as investors’ earlier pessimism seemed exaggerated in light of the most recent clinical and business statements. Sanofi reported a very strong first quarter and could feature among the pharmaceutical suffering a solution to the current health crisis, with Kevzara and several vaccine candidates. Finally, the epidemic has accelerated the shift toon-line drugs sales, a trend that has been favourable to Shop Apotheke and Zur Rose during the month.



as of end of April 2020


Quarterly review

Q1 commentaries